These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 11796549)
1. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Nakamura M; Endo H; Nasu M; Arakawa N; Segawa T; Hiramori K Heart; 2002 Feb; 87(2):131-5. PubMed ID: 11796549 [TBL] [Abstract][Full Text] [Related]
2. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. Vasan RS; Benjamin EJ; Larson MG; Leip EP; Wang TJ; Wilson PW; Levy D JAMA; 2002 Sep; 288(10):1252-9. PubMed ID: 12215132 [TBL] [Abstract][Full Text] [Related]
3. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Niinuma H; Nakamura M; Hiramori K Cardiology; 1998 Oct; 90(2):89-94. PubMed ID: 9778544 [TBL] [Abstract][Full Text] [Related]
4. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Ng LL; Loke I; Davies JE; Khunti K; Stone M; Abrams KR; Chin DT; Squire IB Eur J Heart Fail; 2003 Dec; 5(6):775-82. PubMed ID: 14675856 [TBL] [Abstract][Full Text] [Related]
5. B-type natriuretic peptide testing for structural heart disease screening: a general population-based study. Nakamura M; Tanaka F; Sato K; Segawa T; Nagano M J Card Fail; 2005 Dec; 11(9):705-12. PubMed ID: 16360967 [TBL] [Abstract][Full Text] [Related]
8. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Omland T; Aakvaag A; Vik-Mo H Heart; 1996 Sep; 76(3):232-7. PubMed ID: 8868981 [TBL] [Abstract][Full Text] [Related]
9. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Lubien E; DeMaria A; Krishnaswamy P; Clopton P; Koon J; Kazanegra R; Gardetto N; Wanner E; Maisel AS Circulation; 2002 Feb; 105(5):595-601. PubMed ID: 11827925 [TBL] [Abstract][Full Text] [Related]
10. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Yamamoto K; Burnett JC; Jougasaki M; Nishimura RA; Bailey KR; Saito Y; Nakao K; Redfield MM Hypertension; 1996 Dec; 28(6):988-94. PubMed ID: 8952587 [TBL] [Abstract][Full Text] [Related]
11. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Davidson NC; Naas AA; Hanson JK; Kennedy NS; Coutie WJ; Struthers AD Am J Cardiol; 1996 Apr; 77(10):828-31. PubMed ID: 8623734 [TBL] [Abstract][Full Text] [Related]
12. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide]. Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693 [TBL] [Abstract][Full Text] [Related]
13. The influence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fibrillation. Bakowski D; Wozakowska-Kaplon B; Opolski G Pacing Clin Electrophysiol; 2009 Jun; 32(6):745-52. PubMed ID: 19545336 [TBL] [Abstract][Full Text] [Related]
14. Possible role of BNP for an early diagnosis of asymptomatic left ventricular dysfunction: a retrospective study. De Vecchis R; Esposito C; Ariano C; Di Biase G Minerva Cardioangiol; 2014 Apr; 62(2):147-59. PubMed ID: 24686994 [TBL] [Abstract][Full Text] [Related]
15. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762 [TBL] [Abstract][Full Text] [Related]
16. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Hedberg P; Lönnberg I; Jonason T; Nilsson G; Pehrsson K; Ringqvist I Am Heart J; 2004 Sep; 148(3):524-9. PubMed ID: 15389243 [TBL] [Abstract][Full Text] [Related]
17. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Epshteyn V; Morrison K; Krishnaswamy P; Kazanegra R; Clopton P; Mudaliar S; Edelman S; Henry R; Maisel A Diabetes Care; 2003 Jul; 26(7):2081-7. PubMed ID: 12832317 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Muders F; Kromer EP; Griese DP; Pfeifer M; Hense HW; Riegger GA; Elsner D Am Heart J; 1997 Sep; 134(3):442-9. PubMed ID: 9327700 [TBL] [Abstract][Full Text] [Related]
19. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. Falcão LM; Pinto F; Ravara L; van Zwieten PA J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247 [TBL] [Abstract][Full Text] [Related]
20. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. Costello-Boerrigter LC; Boerrigter G; Redfield MM; Rodeheffer RJ; Urban LH; Mahoney DW; Jacobsen SJ; Heublein DM; Burnett JC J Am Coll Cardiol; 2006 Jan; 47(2):345-53. PubMed ID: 16412859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]